How to buy GW Pharmaceuticals shares
Own GW Pharmaceuticals shares in just a few minutes.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
GW Pharmaceuticals plc is a drug manufacturers-general business with stocks listed in the US. GW Pharmaceuticals shares (GWPH) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
How to buy shares in GW Pharmaceuticals
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for GW Pharmaceuticals. Find the share by name or ticker symbol: GWPH. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until GW Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of GW Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of GW Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- GW Pharmaceuticals key stats
- Compare share trading platforms
- Is GW Pharmaceuticals stock a buy or sell?
- GW Pharmaceuticals performance over time
- Can I short GW Pharmaceuticals shares?
- Are GW Pharmaceuticals shares over-valued?
- GW Pharmaceuticals's financials
- How volatile are GW Pharmaceuticals shares?
- Does GW Pharmaceuticals pay a dividend?
- Other common questions
GW Pharmaceuticals share priceUse our graph to track the performance of GWPH stocks over time.
GW Pharmaceuticals shares at a glance
|52-week range||US$87.0655 - US$219.5696|
|50-day moving average||US$218.2248|
|200-day moving average||US$167.5564|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$1.065|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy GW Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is GW Pharmaceuticals under- or over-valued?
Valuing GW Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GW Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GW Pharmaceuticals's PEG ratio
GW Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.37. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GW Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GW Pharmaceuticals financials
|Revenue TTM||US$559 million|
|Gross profit TTM||US$489.7 million|
|Return on assets TTM||-4.58%|
|Return on equity TTM||-9.62%|
|Market capitalisation||US$6.8 billion|
TTM: trailing 12 months
Shorting GW Pharmaceuticals shares
There are currently 693,731 GW Pharmaceuticals shares held short by investors – that's known as GW Pharmaceuticals's "short interest". This figure is 5.2% up from 659,630 last month.
There are a few different ways that this level of interest in shorting GW Pharmaceuticals shares can be evaluated.
GW Pharmaceuticals's "short interest ratio" (SIR)
GW Pharmaceuticals's "short interest ratio" (SIR) is the quantity of GW Pharmaceuticals shares currently shorted divided by the average quantity of GW Pharmaceuticals shares traded daily (recently around 603244.34782609). GW Pharmaceuticals's SIR currently stands at 1.15. In other words for every 100,000 GW Pharmaceuticals shares traded daily on the market, roughly 1150 shares are currently held short.
However GW Pharmaceuticals's short interest can also be evaluated against the total number of GW Pharmaceuticals shares, or, against the total number of tradable GW Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GW Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 GW Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable GW Pharmaceuticals shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against GW Pharmaceuticals.
Find out more about how you can short GW Pharmaceuticals stock.
GW Pharmaceuticals share dividends
We're not expecting GW Pharmaceuticals to pay a dividend over the next 12 months.
GW Pharmaceuticals share price volatility
Over the last 12 months, GW Pharmaceuticals's shares have ranged in value from as little as US$87.0655 up to US$219.5696. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GW Pharmaceuticals's is 1.6492. This would suggest that GW Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
GW Pharmaceuticals overview
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Frequently asked questions
More guides on Finder
Amazon Prime Day Australia 2021: All the best deals from Day 2
Here are all the best deals from Amazon Prime Day Australia's second day - including the return of dirt-cheap Nintendo Switch consoles.
Amazon Prime Day’s best deals on big-ticket items: Up to 46% off
From segways to stand up paddle boards, these are the best Prime Day savings on the most expensive items.
Nacon RIG 500 Pro HC Gen 2 review: Super comfortable gaming headphones
The Nacon Rig 500 Pro HC headphones have wide console and PC compatibility, Dolby Atmos licensing and a genuinely comfortable design, even for longer gaming sessions.
Oppo Find X3 Neo 5G review: Oppo’s better flagship phone
The Oppo Find X3 Neo lacks the utter flagship features of the Find X3 Pro, but you won't miss them, while you will enjoy its lower price point.
7 health insurance deals to save you money at tax time
Avoid the MLS tax and get a rebate by taking out health insurance. Here are 7 deals that’ll save you money on your tax returns.
Today’s ASX top stocks: Milton Corporation (MLT ↑16.0%), Oneview Healthcare (ONE ↑12.8%)
The 10 biggest movers on the ASX for Tuesday 22 June 2021.
Mobile plans are now more expensive, but here’s a hack to save $200 a year
Telstra, Optus and Vodafone keep raising their prices even as the rest of the market is more affordable than ever.
Prime Day VR gaming deal: $60 off the Oculus Quest 2
Amazon is selling the standalone Oculus Quest 2 virtual-reality headset for $432.12. You can also score $77 off the 256GB version.
Barefoot Investor: How to watch Scott Pape’s Money Movement docu-series online
This fresh docu-series features the one and only Barefoot Investor.
Ask an Expert